相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
Peter Schmid et al.
LANCET ONCOLOGY (2020)
The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice
Paula Gonzalez-Ericsson et al.
JOURNAL OF PATHOLOGY (2020)
Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer
Emily S. Reisenbichler et al.
MODERN PATHOLOGY (2020)
Clinical and pathologic features associated with PD-L1 (SP142) expression in stromal tumor-infiltrating immune cells of triple-negative breast carcinoma
Raza Syed Hoda et al.
MODERN PATHOLOGY (2020)
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
Javier Cortes et al.
LANCET (2020)
Positive correlation between programmed death ligand-1 and p53 in triple-negative breast cancer
Yan Zeng et al.
ONCOTARGETS AND THERAPY (2019)
Radiomics Signature on Magnetic Resonance Imaging: Association with Disease-Free Survival in Patients with Invasive Breast Cancer
Hyunjin Park et al.
CLINICAL CANCER RESEARCH (2018)
Triple negative breast cancer - prognostic role of immune-related factors: a systematic review
Elisabeth Specht Stovgaard et al.
ACTA ONCOLOGICA (2018)
Tumor-infiltrating lymphocyte composition, organization and PD-1/PD-L1 expression are linked in breast cancer
Laurence Buisseret et al.
ONCOIMMUNOLOGY (2017)
The CD4/CD8 ratio of tumor-infiltrating lymphocytes at the tumor-host interface has prognostic value in triple-negative breast cancer
Kai Wang et al.
HUMAN PATHOLOGY (2017)
Role of tumor microenvironment in triple-negative breast cancer and its prognostic significance
Tianjian Yu et al.
CHINESE JOURNAL OF CANCER RESEARCH (2017)
Increased CD4 and CD8-positive T cell infiltrate signifies good prognosis in a subset of triple-negative breast cancer
Hirofumi Matsumoto et al.
BREAST CANCER RESEARCH AND TREATMENT (2016)
Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer
In Hae Park et al.
CLINICAL BREAST CANCER (2016)
Prognostic significance of PD-L1 and PD-L2 in breast cancer
Mauricio Z. Baptista et al.
HUMAN PATHOLOGY (2016)
Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes A Systematic Review
Sasha E. Stanton et al.
JAMA ONCOLOGY (2016)
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
R. Salgado et al.
ANNALS OF ONCOLOGY (2015)
Association between CD8+T-cell infiltration and breast cancer survival in 12 439 patients
H. R. Ali et al.
ANNALS OF ONCOLOGY (2014)
The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis
Ezzeldin M. Ibrahim et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
PD-L1 Expression in Triple-Negative Breast Cancer
Elizabeth A. Mittendorf et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Tumor-Infiltrating CD8+ Lymphocytes Predict Clinical Outcome in Breast Cancer
Sahar M. A. Mahmoud et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
分享论文
